NL-OMON56429招募中不适用
A Phase 1a/1b Open label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors - GO41596
Genentech Inc. (een lid van de Roche Group)0 个研究点目标入组 32 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Age >= 18 years at time of signing Informed Consent Form
- •ECOG Performance Status of 0 or 1
- •Life expectancy >= 12 weeks
- •Adequate hematologic and end-organ function
- •For patients receiving therapeutic anticoagulation: stable anticoagulant
- •Negative serum pregnancy test for women of childbearing potential: agreement
- •to remain abstinent (refrain from heterosexual intercourse) or use contraception
- •For men: agreement to remain abstinent (refrain from heterosexual
- •intercourse) or use a condom
- •Histologically confirmed locally advanced, recurrent, or metastatic incurable
- •solid tumor malignancy
- •Measurable disease per RECIST v1.1
排除标准
- •Pregnant or breastfeeding, or intending to become pregnant during the study
- •Significant cardiovascular disease
- •Current treatment with medications that prolong the QT interval
- •Known clinically significant liver disease
- •Poorly controlled Type 2 diabetes mellitus
- •Symptomatic, untreated, or actively progressing CNS metastases
- •History of leptomeningeal disease
- •History of malignancy other than disease under study within 3 years prior to
- •Active or history of autoimmune disease or immune deficiency
- •Active tuberculosis, hepatitis B, hepatitis C, or known/suspected Epstein
- •Barr virus infection
- •Positive test for HIV infection
- •Prior allogeneic stem cell or solid organ transplantation
研究者
相似试验
尚未招募
1 期
A Phase 1, Single Centre, Open Label, Multiple Dose Study to Investigate the Safety and Pharmacokinetics of Ziverdox in Healthy VolunteersCOVID-19Respiratory - Other respiratory disorders / diseasesACTRN12624000832572Topelia Aust Ltd8
进行中（未招募）
1 期
A Phase I/II, Multicenter, Open-Label, PK, Safety and Efficacy Study to Evaluate Raltegravir in HIV-1 Infected YouthEUCTR2009-015884-15-Outside-EU/EEAThe National Institute of Allergy and Infectious Diseases (NIAID) and The Eunice Kennedy Shriver NICHD138
进行中（未招募）
不适用
urasidone for the treatment of schizophrenia in paediatric patientsschizophreniaEUCTR2013-001523-39-Outside-EU/EEASunovion Pharmaceuticals Inc.100
进行中（未招募）
1 期
Phase 1/2 Open Label solid tumour Safety and Tolerability study.Advanced solid tumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003616-13-DETurning Point Therapeutics, Inc. (a wholly owned subsidiary of Bristol Myers Squibb company)630
招募中
2 期
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)Advanced solid Tumors harboring ALK, ROS1 or NTRK1-3 rearrangementsAdvanced solid tumors. CancerNL-OMON54586Turning Point Therapeutics (a wholly owned subsidiary of Bristol Myers Squibb company)23